Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title:Benzimidazole compound crystal
Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Inventor(s): Fujishima; Akira (Hyogo, JP), Aoki; Isao (Hyogo, JP), Kamiyama; Keiji (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Filing Date:Aug 22, 2012
Application Number:13/591,992
Claims:1. A method for producing a crystal of a compound of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or salt thereof or a hydrate thereof, which comprises: subjecting a racemate of the compound of 2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimid- azole to an optical resolution so as to obtain (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benz- imidazole as in an amorphous form; dissolving the compound in the amorphous form in a solvent so as to obtain a solution of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benz- imidazole dissolved in the solvent; concentrating the solution or adding water to the solution so as to crystallize (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benz- imidazole; and isolating a crystal of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benz- imidazole from the solution or the solution to which the water is added, wherein the solvent is at least one solvent selected from the group consisting of acetonitrile, acetone, and water, and (i) if the solvent is acetonitrile, the solvent is gradually evaporated at room temperature for the crystallization of the compound, whereby the crystal of the compound is produced, (ii) if the solvent is acetone, water is added to the solution for the crystallization of the compound, whereby the crystal of the compound is produced, and (iii) if the solvent is ethanol, water is added to the solution for the crystallization of the compound, whereby the crystal of the hydrate of the compound is produced.

2. The method according to claim 1, wherein the optical resolution is carried out by using a chiral column.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: